Trial Profile
A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) or Placebo in Participants With Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 May 2022
Price :
$35
*
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Bladder cancer; Carcinoma; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-672/ECHO-307
- Sponsors Incyte Corporation
- 09 Dec 2021 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI183884).
- 26 Aug 2020 Status changed from active, no longer recruiting to completed.
- 08 Jul 2020 This trial has been completed in France, according to European Clinical Trials Database.